
Paul Howe
Founder & CEOLeads invention, company vision and commercial development.
An Australian biotechnology research platform, owned by Howe Invest Pty Ltd, progressing peptide-directed materials toward independent evidence and industrial application.
A concise introduction to Āltika, its BSSF research programme and its owner, Howe Invest Pty Ltd.
PDF · 2 pages · November 2026
Public overview · Research status dated 29 October 2026
Based in Bibra Lake, Western Australia, Āltika brings biotechnology research and industrial ambition together.
Āltika Biotech is owned by Howe Invest Pty Ltd. Howe Invest provides the corporate ownership, governance and commercial framework behind the platform and commercialises the end products described in its corporate materials.
Our flagship programme, BSSF, explores a new route to solid-state electrolyte manufacturing. We advance commercial decisions through experimental milestones.

Leads invention, company vision and commercial development.

Supports company governance, business operations and execution.

Leads alternative asset opportunities and commercial expansion across Australia and New Zealand.
We distinguish research agreements, supplier relationships and future commercial opportunities.
Research collaboration for independent physical validation, led by Dr Muhammad Rizwan Azhar. The October 2026 materials report an active agreement and experimental clearance.
Australian peptide synthesis supplier. The reported physical synthesis milestone provides material for the next research stage.
We welcome capability in material evaluation, pilot engineering, qualification and supply. These are engagement opportunities; customer contracts or offtake are not represented.